Accéder au contenu
Merck

Passer à

M005

S-(+)-Deprenyl hydrochloride

solid

Se connecter pour consulter les tarifs organisationnels et contractuels.

A propos de cet article

Formule empirique (notation de Hill) :
C13H17N · HCl
Numéro CAS:
Poids moléculaire :
223.74
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:


form

solid

optical activity

[α]24/D +11.84°, c = 0.1 in H2O(lit.)

color

white

solubility

H2O: soluble

SMILES string

Cl.C[C@@H](Cc1ccccc1)N(C)CC#C

Biochem/physiol Actions

Less active enantiomer of deprenyl.


Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents



J W Tetrud et al.
Science (New York, N.Y.), 245(4917), 519-522 (1989-08-04)
The effects of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a neurotoxin that produces the symptoms of Parkinson's disease, can be fully prevented in experimental animals by inhibiting monoamine oxidase B. On the basis of this observation, a double-blind, placebo-controlled study in patients with early
R E Heikkila et al.
Nature, 311(5985), 467-469 (1984-10-04)
1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) causes degeneration of the dopaminergic nigrostriatal pathway in several animal species, including humans, monkeys and mice. Changes observed after MPTP administration include marked decrements in the neostriatal content of dopamine and its major metabolites, dihydroxyphenylacetic acid and homovanillic
Jorge A Zavala et al.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 19(9), 1298-1299 (2012-06-23)
Pramipexole is a non-ergot dopamine agonist that is used frequently as a single therapy or in combination for the management of Parkinson's disease. Common side effects are daytime drowsiness, hypotension, hallucinations and compulsive behaviour. We describe a patient who developed